Impact of the high baseline anti-A/B antibody titer on the clinical outcomes in ABO-incompatible living donor liver transplantation (TTS 2026) - Sep 17, 2026 - Pres time: Sep 23, 2026; 08:51 AM - 08:56 AM; Location: Room C4.5; 409; "Two centers used a protocol composed of rituximab, plasmapheresis, and/or splenectomy... Although, the patients with high baseline anti-A/B titer showed the higher tendency of postoperative antibody rebound, the baseline and rebound anti-A/B titer may not be as important factors for clinical outcomes of ABOi LDLT if appropriate desensitization is performed. Antibody rebound rise"
Clinical • Clinical data • Antibody-mediated Rejection • Transplantation
|
|
Jai Young Cho1; Hae Won Lee1; Boram Lee1
|